Tenet Healthcare's Beats Wall Street Estimates In Q4, Issues Underwhelming Guidance

• Tenet Healthcare Corp's (NYSE: THC) Q4 FY22 adjusted EPS came in at $1.96, down from $2.70 a year ago and beating the consensus of $1.23.

• Net operating revenue reached $4.99 billion, up 2.76% Y/Y, beating the consensus of $4.94 billion.

• Hospital segment sales declined 1.8% to $3.84 billion due to lower COVID-related volume and acuity, partially offset by higher adjusted admissions and improved pricing yield.

• The ambulatory care segment's net operating revenues increased by 25.7%, driven by additional revenues from the SurgCenter Development (SCD) acquisition completed in December 2021, service line growth, and improved pricing yield.

• Same-facility system-wide ambulatory surgical cases increased by 0.7% versus Q4 2021; Same-hospital adjusted admissions increased by 2.9% versus Q4 2021.

• Outlook: Tenet forecasts FY23 revenue of $19.7 - $20.1 billion versus the consensus of $20.11 billion. It expects EPS of $4.68 - $5.85 Vs. $5.64 estimate.

• For Q1 FY23, the company anticipates revenue of $4.7-$4.9 billion vs. $4.97 billion estimate and EPS of $1.00 - $1.23 vs. $1.34 estimate.

• Price Action: THC shares are down 4.36% at $52 premarket on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Tenet Healthcare's Beats Wall Street Estimates In Q4, Issues Underwhelming Guidance originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.